Literature DB >> 20598014

Improving bladder cancer treatment with radiotherapy using separate intensity modulated radiotherapy plans for boost and elective fields.

D C van Rooijen1, J B van de Kamer, M C C M Hulshof, C C E Koning, A Bel.   

Abstract

The aim of this study is to investigate to what extent IMRT can decrease the dose to the organs at risk in bladder cancer treatment compared with conformal treatment while making separate treatment plans for the elective field and the boost. Special attention is paid to sparing small intestines. Twenty patients who were treated with the field-in-field technique (FiF) were re-planned with intensity modulated radiotherapy (IMRT) using five and seven beams, respectively. Separate treatment plans were made for the elective field (including the pelvic lymph nodes) and the boost, which enables position correction for bone and tumour separately. The prescribed dose was 40 Gy to the elective field and 55 or 60 Gy to the planning target volume (PTV). For bladder and rectum, V(45Gy) and V(55Gy) were compared, and for small intestines, V(25Gy) and V(40Gy.) The dose distribution with IMRT conformed better to the shape of the target. There was no significant difference between the techniques in dose to the healthy bladder. The median V(40Gy) of the small intestines decreased from 114 to 66 cc (P = 0.001) with five beam IMRT, and to 55 cc (P = 0.001) with seven beam IMRT compared with FiF. V(45Gy) for rectum decreased from 34.2% to 17.5% (P = 0.004) for both five and seven beam plans, while V(55Gy) for rectum remained the same. With IMRT, a statistically significant dose decrease to the small intestines can be achieved while covering both tumour and elective PTV adequately.

Entities:  

Mesh:

Year:  2010        PMID: 20598014     DOI: 10.1111/j.1754-9485.2010.02169.x

Source DB:  PubMed          Journal:  J Med Imaging Radiat Oncol        ISSN: 1754-9477            Impact factor:   1.735


  5 in total

1.  Radiotherapy in muscle-invasive bladder cancer: the latest research progress and clinical application.

Authors:  Shuo Zhang; Yong-Hua Yu; Yong Zhang; Wei Qu; Jia Li
Journal:  Am J Cancer Res       Date:  2015-01-15       Impact factor: 6.166

2.  Intensity modulated radiotherapy for elderly bladder cancer patients.

Authors:  Chen-Hsi Hsieh; Shiu-Dong Chung; Pei-Hui Chan; Siu-Kai Lai; Hsiao-Chun Chang; Chi-Huang Hsiao; Le-Jung Wu; Ngot-Swan Chong; Yu-Jen Chen; Li-Ying Wang; Yen-Ping Hsieh; Pei-Wei Shueng
Journal:  Radiat Oncol       Date:  2011-06-16       Impact factor: 3.481

3.  Promising results with image guided intensity modulated radiotherapy for muscle invasive bladder cancer.

Authors:  D Whalley; H Caine; P McCloud; L Guo; A Kneebone; T Eade
Journal:  Radiat Oncol       Date:  2015-09-25       Impact factor: 3.481

4.  Clinical results of conformal versus intensity-modulated radiotherapy using a focal simultaneous boost for muscle-invasive bladder cancer in elderly or medically unfit patients.

Authors:  Lotte J Lutkenhaus; Rob M van Os; Arjan Bel; Maarten C C M Hulshof
Journal:  Radiat Oncol       Date:  2016-03-18       Impact factor: 3.481

5.  Phase I Clinical Trial of Everolimus Combined with Trimodality Therapy in Patients with Muscle-Invasive Bladder Cancer.

Authors:  Bassel G Bachir; Luis Souhami; Jose João Mansure; Fabio Cury; Marie Vanhuyse; Fadi Brimo; Armen G Aprikian; Simon Tanguay; Jeremy Sturgeon; Wassim Kassouf
Journal:  Bladder Cancer       Date:  2017-04-27
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.